Celnova Pharma Selected by Alnylam Pharmaceuticals for Exclusive Distribution Agreement in Colombia for GIVLAARI® (givosiran), the First-in-Class RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria (AHP)
− GIVLAARI is the First Therapy Proven to Prevent AHP Attacks – Bogota, Colombia, November 18th, 2020 – Celnova Pharma, a Latin American company focused in complex therapeutic areas, announced today that the company has entered into an exclusive distribution agreement with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) for GIVLAARI® (givosiran), a first-in-class RNAi therapeutic for the treatment […]